Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7305, USA.
J Surg Oncol. 2010 Dec 15;102(8):946-54. doi: 10.1002/jso.21653.
Resection of metastatic colorectal cancer hepatic lesions has gained support as surgical advances have made resections safer. Subsequently, the use of neoadjuvant therapy to cytoreduce tumors coupled with improved medical therapy has enhanced resection rates leading to improved outcomes. In "unresectable" disease, the addition of biologic therapies has further enhanced antitumor response, resulting in successful disease resection in certain patients. This review examines approaches to the neoadjuvant management of colorectal liver metastases with systemic therapies.
结直肠肝转移灶切除术得到了支持，因为外科技术的进步使切除术更安全。随后，新辅助治疗联合细胞减灭术以及改进的内科治疗提高了切除术的比例，从而改善了患者的预后。对于“不可切除”的疾病，添加生物治疗进一步增强了抗肿瘤反应，从而使某些患者成功切除了疾病。本文综述了系统治疗在结直肠肝转移新辅助治疗中的应用方法。
